Lemaitre Vascular Inc. Insider Trading

LMAT

Last 12 months

Insiders sold $30M and bought nothing on the open market.

73% of the selling was scheduled in advance under 10b5-1 plans. Chairman and CEO George W Lemaitre sold $5.03M on May 8 outside a plan. The last open-market buy by an executive or director was in Aug 2020.

Net open-market

−$30M

0 buys · 9 sales

Under a 10b5-1 plan

73%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Aug 2020

Aug 26, 2020

Get an email when LMAT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 7 – 8	George W Lemaitre Chairman and CEO	SoldNo plan 2 parts	46,481	$108.27 average	$5.03M	3.1%	Form 4
May 8	Trent G Kamke Senior V. P., Operations	SoldNo plan	2,928	$107.00	313K	44%	Form 4
May 7	Bridget A Ross Director	SoldNo plan	5,044	$111.10	560K	56%	Form 4
May 7	Lawrence J Jasinski Director	SoldNo plan	3,943	$110.00	434K	46%	Form 4
Mar 11	Trent G Kamke Senior V. P., Operations	SoldNo plan	2,625	$108.50	285K	28%	Form 4
Mar 11	David B Roberts President and Director	SoldNo plan	3,312	$107.68	357K	18%	Form 4
Feb 26 – Mar 2	George W Lemaitre Chairman and CEO	Sold10b5-1 plan 2 parts	205,930	$107.05 average	$22M	12%	Form 4
Feb 27	Trent G Kamke Senior V. P., Operations	SoldNo plan	1,044	$110.29	115K	14%	Form 4
Feb 27	David B Roberts President and Director	SoldNo plan	8,464	$106.80	904K	32%	Form 4
Aug 12, 2025	Lawrence J Jasinski Director	SoldNo plan	976	$92.78	91K	17%	Form 4
Aug 11, 2025	David B Roberts President and Director	SoldNo plan 3 parts	10,815	$92.38 average	999K	38%	Form 4
Aug 8, 2025 – Aug 11, 2025	John A Roush Director	SoldNo plan 3 parts	7,500	$92.67 average	695K	72%	Form 4
Aug 8, 2025	Bridget A Ross Director	SoldNo plan	2,500	$94.00	235K	46%	Form 4
Aug 6, 2025	George W Lemaitre Chairman and CEO	Sold10b5-1 plan	100,000	$93.51	$9.35M	5.5%	Form 4
May 16, 2025 – May 20, 2025	George W Lemaitre Chairman and CEO	SoldNo plan 5 parts	100,000	$85.57 average	$8.56M	5.2%	Form 4
May 12, 2025	Bridget A Ross Director	SoldNo plan	3,750	$83.20	312K	56%	Form 4
Mar 12, 2025 – Mar 13, 2025	Trent G Kamke Senior V. P., Operations	SoldNo plan 3 parts	6,529	$80.42 average	525K	63%	Form 4
Mar 4, 2025	Lawrence J Jasinski Director	SoldNo plan	3,142	$92.00	289K	55%	Form 4
Nov 20, 2024	Lawrence J Jasinski Director	SoldNo plan	198	$103.50	20K	3.7%	Form 4
Nov 15, 2024	Bridget A Ross Director	SoldNo plan	3,750	$101.47	381K	62%	Form 4
Nov 13, 2024	Martha Shadan Director	SoldNo plan 2 parts	1,466	$103.37 average	152K	53%	Form 4

May 7 – 8No plan
George W Lemaitre
Chairman and CEO · sold 46,481 at avg $108.27
$5.03M
3.1% of stake
May 8No plan
Trent G Kamke
Senior V. P., Operations · sold 2,928 at $107.00
313K
44% of stake
May 7No plan
Bridget A Ross
Director · sold 5,044 at $111.10
560K
56% of stake
May 7No plan
Lawrence J Jasinski
Director · sold 3,943 at $110.00
434K
46% of stake
Mar 11No plan
Trent G Kamke
Senior V. P., Operations · sold 2,625 at $108.50
285K
28% of stake
Mar 11No plan
David B Roberts
President and Director · sold 3,312 at $107.68
357K
18% of stake
Feb 26 – Mar 210b5-1 plan
George W Lemaitre
Chairman and CEO · sold 205,930 at avg $107.05
$22M
12% of stake
Feb 27No plan
Trent G Kamke
Senior V. P., Operations · sold 1,044 at $110.29
115K
14% of stake
Feb 27No plan
David B Roberts
President and Director · sold 8,464 at $106.80
904K
32% of stake
Aug 12, 2025No plan
Lawrence J Jasinski
Director · sold 976 at $92.78
91K
17% of stake
Aug 11, 2025No plan
David B Roberts
President and Director · sold 10,815 at avg $92.38
999K
38% of stake
Aug 8, 2025 – Aug 11, 2025No plan
John A Roush
Director · sold 7,500 at avg $92.67
695K
72% of stake
Aug 8, 2025No plan
Bridget A Ross
Director · sold 2,500 at $94.00
235K
46% of stake
Aug 6, 202510b5-1 plan
George W Lemaitre
Chairman and CEO · sold 100,000 at $93.51
$9.35M
5.5% of stake
May 16, 2025 – May 20, 2025No plan
George W Lemaitre
Chairman and CEO · sold 100,000 at avg $85.57
$8.56M
5.2% of stake
May 12, 2025No plan
Bridget A Ross
Director · sold 3,750 at $83.20
312K
56% of stake
Mar 12, 2025 – Mar 13, 2025No plan
Trent G Kamke
Senior V. P., Operations · sold 6,529 at avg $80.42
525K
63% of stake
Mar 4, 2025No plan
Lawrence J Jasinski
Director · sold 3,142 at $92.00
289K
55% of stake
Nov 20, 2024No plan
Lawrence J Jasinski
Director · sold 198 at $103.50
20K
3.7% of stake
Nov 15, 2024No plan
Bridget A Ross
Director · sold 3,750 at $101.47
381K
62% of stake
Nov 13, 2024No plan
Martha Shadan
Director · sold 1,466 at avg $103.37
152K
53% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LMAT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with LMAT

CompareIntrinsic value

KIDSOrthoPediatrics Corp.

$33.51+6.69%45

SKINSkinHealth Systems Inc.

$11.05+6.76%42

CERSCerus Corporation

$2.42+3.21%32

SIBNSi-Bone Inc.

$24.95+4.96%40

HTFLHeartFlow, Inc.

$56.57+3.99%49

TMCITreace Medical Concepts, Inc.

$4.50+5.14%14

ANGOAngiodynamics Inc.

$12.27+4.60%40

PRCTProcept BioRobotics Corporation

$21.66+7.39%40

Held by ETFs

LMAT is in 72 US ETFs. The largest of them, with LMAT's weight in each:

Spot a number that looks wrong? Check it in LMAT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LMAT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.